Literature DB >> 28491898

A Cross-sectional population-based investigation into behavioral change in amyotrophic lateral sclerosis: subphenotypes, staging, cognitive predictors, and survival.

Tom Burke1,2, Marta Pinto-Grau1,2, Katie Lonergan1,2, Peter Bede1,2, Meabhdh O'Sullivan1, Mark Heverin1, Alice Vajda1, Russell L McLaughlin3, Niall Pender1,2, Orla Hardiman1,2.   

Abstract

OBJECTIVE: Amyotrophic Lateral Sclerosis (ALS) is a clinically heterogeneous neurodegenerative disorder associated with cognitive and behavioral impairment. The primary aim of this study was to identify behavioral subphenotypes in ALS using a custom designed behavioral assessment tool (Beaumont Behavioural Inventory, BBI). Secondary aims were to (1) investigate the predictive nature of cognitive assessment on behavioral change, (2) report the behavioral profile associated with the C9orf72 expansion, (3) categorize behavioral change through disease staging, and (4) to investigate the relationship between cross-sectional behavioral classification and survival.
METHODS: A cross-sectional population-based research design was applied to examine behavioral data from ALS patients (n = 317) and healthy controls (n = 66). Patients were screened for the C9orf72 repeat expansion. A subcohort of ALS patients completed an extensive cognitive assessment battery (n = 65), to investigate predictors of behavior change. Principal component analysis (PCA) determined factors associated with altered behavior. Survival data were extracted from the Irish ALS register.
RESULTS: No behavioral changes were reported in 180 patients (57%); 95 patients had mild-moderate behavioral change (30%); 42 patients met the cut-off for Clinically Severe Behavioral Change (13%), suggestive of a bvFTD diagnosis. The most frequently endorsed behaviors in ALS were reduced concern for hygiene (36.8%), irritability (36.2%), new unusual habits (33.4%), and increased apathy (31.1%). Five independent factors were identified through factor analysis. Social cognitive performance was predictive of behavior change (P = 0.031), yielding an R2 = 0.188. Behavioral categorization (mild/moderate/severe) at the time of assessment was not associated with survival (P = 0.198).
INTERPRETATION: These data imply the presence of distinct subphenotypes of behavioral change in ALS, which most likely reflect subcategories of extramotor network disruption.

Entities:  

Year:  2017        PMID: 28491898      PMCID: PMC5420811          DOI: 10.1002/acn3.407

Source DB:  PubMed          Journal:  Ann Clin Transl Neurol        ISSN: 2328-9503            Impact factor:   4.511


Introduction

Amyotrophic Lateral Sclerosis (ALS) is a clinically and genetically heterogeneous neurodegenerative disorder, of which cognitive and behavior impairment are core features.1, 2, 3, 4, 5, 6 Executive dysfunction is present in up to 50% of ALS patients, alongside behavioral features associated with frontotemporal dementia (FTD).7, 8 Approximately 13–15% of ALS patients presenting with severe behavior change meet consensus criteria for behavioral variant frontotemporal dementia (bvFTD),9 which negatively impacts on patient survival.7 Behavior change is underreported within the ALS literature,8, 9 as studies often lack a robust methodological design to infer generalizable results.10, 11, 12, 13 A recent systematic review of 21 studies found that mild to moderate behavioral changes are present in 17%–88% of ALS patients without overt dementia.4 The most commonly reported behavior changes in ALS patients are apathy, which is present in up to 60% of patients,12, 14 followed by disinhibition15 and irritability. Direct comparisons of ALS and bvFTD patients suggest that behavioral symptoms are significantly less frequent in ALS,16 though changes in behavior are qualitatively similar between the two groups.15 However, significant correlations between executive dysfunction and behavioral change have been found12, 13 and comorbidity of symptoms is reported.9, 17, 18 Behavior changes are also shown to occur independently of cognitive dysfunction.19 The anatomical degeneration of cortical regions associated with behavioral regulation has been documented in ALS studies20, 21 and have included orbitofrontal, anterior cingulate,19 and prefrontal cortical regions.22 Extensive extramotor pathology has also been demonstrated in ALS cohorts with no detectable behavioral or cognitive change, which most likely reflects presymptomatic gray matter alterations.23 Multi‐parametric imaging studies of the C9orf72 genotype demonstrate orbitofrontal, Broca's area, and cingulate pathology, as well as marked white matter degeneration in the genu of the corpus callosum.24 Correlative imaging studies of behavioral change in ALS demonstrated that apathy scores correlate with bilateral orbitofrontal cortex atrophy, decreased frontal fractional anisotropy,21 and accumbens nucleus atrophy.25 Notwithstanding, there have been few population‐based studies of sufficient magnitude to definitively subcategorize behavioral subphenotypes in ALS, and to determine whether severity of behavioral change affect clinical outcome. The aims of this study were to examine behavioral change in a large population‐based cohort of ALS patients using a recently validated behavioral instrument26, to determine whether distinct subphenotypes of behavioral change can be discerned based on known patterns of network disruption, to consider the cognitive predictors of behavioral change, to investigate whether behavioral change correlate with clinical parameters of disease, and to examine the impact of behavioral change on survival.

Material and Methods

Participants

Recruitment of ALS patients (n = 317) and healthy controls (n = 66) was undertaken using both clinic‐based recruitment, and through the Irish ALS Register.27 Recruitment protocols have been described previously in detail.6 A subcohort of patients underwent neuropsychological assessment outlined in detail in Table 1. All patients were tested within 7.66 ± 10.54 months of diagnosis, and 22.09 ± 16.07 months of first symptom (See Table 2 for further details). Clinical stage was estimated using the King's Staging Criteria.28, 29 Matched healthy controls were recruited as part of a volunteer network (n = 66). Inclusion criterion included possible, probable or definite ALS based on the revised El Escorial Criteria30 with supported neurophysiology. Exclusion criteria included neurological conditions associated with cognitive or behavioral change, and/or high dose psychotropic medications. Patients with a diagnosis of ALSFTD were included; however, FTD patients without overt symptomatology of ALS were not included in this study. All but 9 of 317 patients were screened for the C9orf72 expansion.
Table 1

Details of the neuropsychological battery

Executive dysfunctionImpairment that is two SD below the mean for healthy controls on at least two executive tasks
Stroop colour‐word Test(a) Priming trial: patients presented with a multi‐colored list of color names and asked to read as many words as they can in 2 min. (b) Inhibitory trial: a similar list is presented but color names (e.g., “blue”) are printed in an ink color not denoted by the name (e.g., red). Correct responses in two minutes are recorded
Nonexecutive factors (including bulbar disability) contribute equally to both trials. The difference in scores between the two trials represent the number of responses “lost” due to the delay imposed by the extra executive demands in the inhibitory trial
Brixton spatial anticipation testA rule attainment‐based task whereby the rule in operation cannot be identified by any perceptually salient aspect of the stimuli. It consists of pages showing the same basic array of 10 circles set in two rows of five, with each circle numbered from 1 to 10. The changes in position are governed by a series of simple rules, which vary without warning.
Backward digit spanA measure of auditory attention and working memory. This test is composed of trials where examinees are read strings of digits and are asked to repeat them back aloud. The length of the digit strings is incrementally increased over successive trials
Category fluencyPatients were asked to name as many animals as they could think of in 1 min (spoken only)
Phonemic verbal fluencyWritten/spoken, number of words starting with letter “S” generated in 5 min and number of four letter words starting with letter “C” generated in 4 min. Verbal Fluency Index used to adjust for disability
Memory dysfunctionImpairment that is two SD below the mean for healthy controls on at least four* of the parameters highlighted using +
Logical memory (LM)+LM1 (immediate recall), +LM2 (delayed recall) and +LM retention (retention)
Verbal paired associate (VPA)+VPA1 (immediate recall), +VPA2 (delayed recall) and +VPA retention (retention)
Auditory Delayed Recognition Task+Sum of total recognition scores on Logical Memory and Verbal Paired Associates
California verbal learning tests+Total of five trials, +short delay free recall (immediate recall) +long delay free recall (delayed recall)
Rey‐Osterrieth complex figure testNonverbal memory: parameters used: +immediate and +delayed recall trials
Language dysfunctionImpairment that is two SD below the mean for healthy controls on this task
Boston naming test
Visuospatial dysfunctionImpairment that is two SD below the mean for healthy controls on copy trial of this task
Rey‐Osterrieth Complex Figure Test
Table 2

Baseline demographics of participants Mean ± SD

Demographic variableHealthy controls (N = 66)ALS (N = 317) P
Age at assessment61.39 ± 13.6763.00 ± 11.130.333
Males %45%51%0.023
Years of Education13.51 ± 3.7612.91 ± 3.770.252
Disease onset (%)
Spinal Onset56.7
Bulbar Onset23.2
Respiratory2.9
Time since diagnosis (months)7.66 ± 10.54
Disease duration (months)22.09 ± 16.07
Total ALSFRS‐R (±SD)35.17 ± 7.88
Bulbar total9.42 ± 2.96
Spinal total15.23 ± 5.88
Respiratory total10.51 ± 2.40
Disease staging (as per King's criteria)
Stage 121%
Stage 218%
Stage 314%
Stage 447%
Details of the neuropsychological battery Baseline demographics of participants Mean ± SD All participants provided written consent as per the approved protocol. The work was approved by the Beaumont Hospital Ethics Committee and meets the standards and requirements of the Declaration of Helsinki.

Cognitive, behavioral, and functional assessment

A 41‐item proxy‐report behavioral questionnaire was administered to each participant in this study (The Beaumont Behavioural Inventory: BBI), which was custom designed and validated for use with ALS patients.26 The BBI has high internal consistency (Cronbach's = 0.89), and high sensitivity and specificity (87.9% and 78.8%, respectively) for identifying mild behavior change, and using a cut‐off score of 22.5 can identify ALSFTD (90% sensitivity; 96% specificity). The presence of symptoms is graded on a scale of 1 to 3 (mild; moderate; severe). The results are then categorized based on the total score (No Behavioral Dysfunction ≤6; Mild Behavioral Change 7‐22; Severe Behavioral Dysfunction ≥23). Detailed neuropsychological assessment data were available for a subcohort of participants (n = 65), who were assessed using an extensive battery of standardized neuropsychological measures (Table 1) sensitive to cognitive changes in ALS, as part of a parallel study.6 This cohort underwent cognitive testing as part of a larger study investigating cognitive dysfunction in a population‐based cohort of ALS patients. These patients were recruited using the outlined protocol, and were incident‐based ALS patients. The revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS‐R) is a clinically validated tool used to document disease progression over time and was utilized in this study to compare disease severity within patient groups.31

Statistical analysis

Considering the large cohort of ALS patients recruited to this study, Cronbach's alpha was determined for the BBI as a means of validation. Cronbach's alpha was previously reported for the BBI at 0.89 as reported above. Group comparisons were undertaken using independent sample t‐test and ANOVA. Multiple comparisons were considered for all variables and analyses where relevant. Logistic regression was used to investigate the value of cognitive scores in predicting behavioral impairment. The predictive value of the model was estimated using the C‐statistic. A linear regression was also employed to investigate the predictive value of cognitive outcome data, and measures of mood. All tests were two‐tailed and alpha was set at 0.05. IBM Statistical Package for the Social Sciences (SPSS) 21.0 was used for analyses.

Factor extraction

With regard to statistical power, n = 100 is the recommended minimum number required to undertake a factor analysis.32 However, five respondents per item has also been suggested.33 Considering these data, a Kaiser‐Meyer‐Olkin (KMO) test yielded P = 0.824, suggesting that this study meets these three criteria for sufficient sample size. Principal Components Analysis (PCA) has been previously used within the literature on neurodegenerative diseases, that is, Huntington's disease (HD), to examine behavioral clustering and identify factors/principal components of measurement tools.34 PCA examines the interrelationship of variables, and an orthogonal varimax rotation was employed.35 The method of PCA and varimax rotation was adopted for this study, due to the congruency between observed cognitive and behavioral changes within both HD and ALS,36 as the varimax rotation aims to investigate and address the total variance accounted for by each item, rather than the degree to which each factor is correlated. An oblique rotation method, such as direct oblimin (delta=0), differs in that it investigates the correlations between factors. For completeness, an oblique rotation has been performed and is reported within the supplementary material which will identify the degree to which the factor structures correlate. To decide upon the number of emerging factors, Kaiser's criterion for factors with an eigenvalue of >1 was employed, in line with previously published studies investigating behavioral phenotypes in neurodegenerative diseases.37, 38, 39, 40 The generated scree plot associated with Kaiser's criterion is available as supplementary information (Figure S1).

Results

Prevalence of behavioral change

Of the total ALS cohort (N = 317), 180 patients (57%) had no behavioral dysfunction (BBI ≤6), 95 patients (30%) had mild‐moderate behavioral impairment (BBI = 7–22), and 42 patients (13%) had severe behavioral dysfunction (BBI ≥23) as illustrated in Figure 1. Cronbach's alpha was employed to investigate the reliability of the BBI total score. Our findings are consistent with the validation of the BBI,26 with Cronbach's alpha = 0.906.
Figure 1

Box‐plots representing the behavioral data stratified by severity as nonsignificant behavioral change (n = 180), mild‐moderate behavioral change (n = 95), and clinically severe behavior change (n = 42).

Box‐plots representing the behavioral data stratified by severity as nonsignificant behavioral change (n = 180), mild‐moderate behavioral change (n = 95), and clinically severe behavior change (n = 42). Bulbar‐onset disease had no effect on overall behavioral impairment (P = 0.643) but was associated with higher rates of emotional lability (56.5% vs. 40.8%, P = 0.002). No significant association between behavioral impairment and gender, site of onset, or disease duration, was observed. The most frequently described new‐onset behavior in ALS was emotional lability (44%; P < 0.001), followed by reduced concern for hygiene (36.8%; P < 0.001), irritability (36.2%; P = 0.002), new “unusual habits” (33.4%; P < 0.001), and increased apathy (31.1%; P < 0.001). The classification of “unusual habits” was determined by caregivers, who outlined behaviors that were previously uncharacteristic of the person. The remaining behavioral changes can be seen in Table 3, alongside the caregiver endorsement of mild, moderate, and severe change.
Table 3

Total ALS cohort's behavioral change on BBI (n = 317)

BBI symptomNo change (%)Mild (%)Moderate (%)Severe (%)
Increased irritability 63.820.413.22.6
Less aware of physical senses 84.16.38.31.3
Difficulties with conversation 76.214.56.62.6
Not aware of mistakes 7514.17.93.0
Less reactive to difficulties 68.912.913.64.6
Acts without thinking 7310.98.67.6
Emotional lability 5621.515.66.8
Lack of appropriate embarrassment 77.513.26.62.6
Less Concerned about others 80.310.54.34.9
More selfish behavior 87.17.93.02.0
New unusual habits 66.620.59.33.6
More withdrawn 82.310.55.22.0
Perseverative speech 81.413.14.61.0
Less concerned about hygiene 63.222.47.96.6
More aggressive 83.69.25.22.0
Obsessive Counting96.42.60.30.7
Excessively storing food in mouth 92.84.62.30.3
Eats much more 89.56.53.60.3
Hyperorality97.7110.3
Overly sensitive to stimuli 71.915.710.12.3
New food preferences 81.8133.91.3
Less picky about food 86.69.52.31.6
Difficulty with everyday language 92.62.73.11.6
Smokes more92.62.73.11.6
Change in sexual interest 85.95.23.35.6
Sees/Hears Things/People97.80.70.70.7
New bizarre beliefs95.61.52.90
Repetitious behavior 82.69.84.63.0
Repeats phrases again and again 88.85.34.02.0
Dislikes change in routine 82.511.44.21.9
Seeks social contact 89.55.24.21
Constantly aligns things88.86.63.31.3
Overly concerned with neatness95.72.32.00
Constantly checking clocks etc.93.14.61.60.7
Shows less emotion 84.38.54.62.6
Acts inappropriately in public94.42.62.60.3
Developed unusual rituals99.70.700
Hoards, hides, or collects things93.13.92.60.3
Handles things for no reason97.11.610.3
More distractible 77.513.44.64.6
Mimics/repeats words/phrases93.14.01.31.7

Bold text implies significantly different to controls, at a group level, where P < 0.05. These data were transposed to percentages for ease of viewing after analyses were conducted for significance.

Total ALS cohort's behavioral change on BBI (n = 317) Bold text implies significantly different to controls, at a group level, where P < 0.05. These data were transposed to percentages for ease of viewing after analyses were conducted for significance. Within the patient cohort, ALS patients without behavioral impairment (n = 180), with mild behavioral impairment (n = 95), and severe behavioral impairment (n = 42) were stratified to investigate the most common types of behavior change. Patients exhibiting mild behavior change were also reported to have emotional lability (57%), apathy (48%), and an altered sensory perception to external stimuli (41.1%), according to their primary caregiver. This cohort further exhibited new‐onset unusual habits (44.7%) and less concern for hygiene (52.1%). Patients with severe behavioral impairment were reported to be more apathetic (87.5%), not as aware of mistakes as before (82.5%), more impulsive (82.9%), and less responsive to others' needs (71.4%). Through the itemization of the scale in Table 4, it can be seen that many of the same new‐onset behaviors are endorsed across all groups, with higher frequency in the severely impaired group.
Table 4

ALS cohort stratified by behavioral category, displaying % of endorsed items per group

BBI symptomNo behavior change (n = 180) Mild‐moderate behavioral change (n = 95)Clinically severe behavioral change (n = 42)
Increased irritability35.732.646.3
Less aware of physical senses3.622.353.8
Difficulties with conversation7.736.860
Not aware of mistakes4.736.882.5
Less reactive to difficulties8.348.487.5
Acts without thinking7.736.882.9
Emotional lability28.757.476.2
Lack of appropriate embarrassment6.53365
Less concerned about others0.630.571.4
More selfish behavior1.819.143.9
New unusual habits19.844.766.4
More withdrawn3.621.168.3
Perseverative speech6.526.351.2
Less concerned about hygiene17.252.182.9
More aggressive2.421.161.9
Obsessive counting03.220
Excessively storing food in mouth09.531
Eats much more5.913.722
Hyperorality0.6014.6
Overly sensitive to stimuli (Noise)15.341.151.2
New food preferences5.333.735.7
Less picky about food1.826.331.7
Difficulty with everyday language8.427.765.9
Smokes more4.99.414.3
Change in sexual interest7.917.133.3
Sees/Hears Things/People0311.8
New bizarre beliefs09.117.6
Repetitious behavior4.125.553.7
Repeats phrases again and again012.853.7
Dislikes change in routine4.125.654.8
Seeks social contact1.212.643.9
Constantly aligns things0.613.448.8
Overly concerned with neatness0.64.320
Constantly checking clocks etc.0.68.529.3
Shows less emotion1.222.361
Acts inappropriately in public04.231.7
Developed unusual rituals01.12.6
Hoards, hides, or collects things0.66.335
Handles things for no reason0022
More distractible4.735.865.9
Mimics/Repeats Words/Phrases05.339
ALS cohort stratified by behavioral category, displaying % of endorsed items per group ALS patients were stratified by King's Staging Criteria. Behavioral reports were significantly different between King's stages (P = 0.016). Post hoc analysis showed, on a group level, that caregivers of patients in Stage 4 reported significantly greater behavioral change in patients, compared to caregivers of patients in Stage 1. The distribution of scores on a group level, stratified by severity of behavioral change can be seen in Figure 2.
Figure 2

ALS patient behavioral data stratified by King's stage, and trichotomized by behavioral severity. ALS patients were classified by the King's staging criteria as follows: Stage 1, 21%; Stage 2, 18%; Stage 3 14%; Stage 4, 47%. In Stage 1, 77% had no behavioral change (1.84 ± 2.0), 13% were in the mild‐moderate change category (9.37 ± 3.46), and 10% were in the clinically severe range (39.50 ± 14.57); Stage 2, 67% of patients had no behavioral change (1.63 ± 1.93), 24% had mild‐moderate behavioral change (11.41 ± 4.92), and 8% were within the clinically severe range (35.50 ± 12.34); Stage 3 patients recorded mostly no behavioral change (50%: 2.1 ± 2.22), with 32% in the mild‐moderate range (12.38 ± 4.83), and 18% (36.28 ± 11.78) in the clinically severe range; Stage 4, 46% of the cohort has no behavioral change (2.93 ± 2.09), 40% exhibited mild‐moderate behavioral change (13.34 ± 4.48), with 14% within the clinically severe range (33.57 ± 12.64).

ALS patient behavioral data stratified by King's stage, and trichotomized by behavioral severity. ALS patients were classified by the King's staging criteria as follows: Stage 1, 21%; Stage 2, 18%; Stage 3 14%; Stage 4, 47%. In Stage 1, 77% had no behavioral change (1.84 ± 2.0), 13% were in the mild‐moderate change category (9.37 ± 3.46), and 10% were in the clinically severe range (39.50 ± 14.57); Stage 2, 67% of patients had no behavioral change (1.63 ± 1.93), 24% had mild‐moderate behavioral change (11.41 ± 4.92), and 8% were within the clinically severe range (35.50 ± 12.34); Stage 3 patients recorded mostly no behavioral change (50%: 2.1 ± 2.22), with 32% in the mild‐moderate range (12.38 ± 4.83), and 18% (36.28 ± 11.78) in the clinically severe range; Stage 4, 46% of the cohort has no behavioral change (2.93 ± 2.09), 40% exhibited mild‐moderate behavioral change (13.34 ± 4.48), with 14% within the clinically severe range (33.57 ± 12.64).

Cognitive function as a predictor of behavior change

A subcohort of ALS patients underwent detailed cognitive evaluation (n = 65) as part of a parallel study investigating ALS patients' cognitive function. All patients enrolled within the cognitive study, which was population‐based, who also completed the BBI were considered for this study. Twenty‐four patients had evidence of single‐ or multi‐domain cognitive impairment (37%). Of those who were cognitively intact (n = 41), 30% had evidence of mild‐moderate behavioral change (n = 12), with 7% reported to have severe behavioral impairment (n = 3). Executive dysfunction was more likely to be an evidence in those with behavioral impairment (P = 0.001). Spearman correlation analyses revealed that patients exhibiting severe behavioral impairment performed poorly on the Stroop Colour‐Word Interference Task (r = −0.549, P < 0.0001), VFI (r = 0.504, P < 0.0001) and, to a lesser extent, the Brixton Spatial Anticipation task (r = −0.300, P = 0.036). The Brixton Spatial Anticipation task did not meet the more stringent cut‐off when controlling for multiple comparisons within the cognitive data. Table S1 reports cognitive outcome data for this subcohort in greater detail, inclusive of significant and nonsignificant findings in relation to behavioral change. Severe behavioral impairment was significantly correlated with poor scores on The Reading the Mind in the Eye Test (RMET), which is a task of social cognition (r = −0.453, P = 0.002). A binary logistic regression model defined a predictive value of abnormal performance on measures of executive function, that is, the Stroop task, verbal fluency index, and RMET with the BBI as the outcome variable (P = 0.011, C‐statistic = 0.794). A significant predictor of behavioral dysfunction in this model was impaired performance on the RMET (P = 0.031, odds ratio = 8.8, 95% CI: 1.2–63.7). A linear regression model was then created to include cognitive outcome data, and the Hospital Anxiety and Depression Scale (HADS: Table S1). The only significant predictor within the battery of tests was the RMET (P = 0.031), yielding an individual R2 =  0.188, with the total battery yielding R 2 = 0.616, when the BBI total sum score was the specific outcome variable. Variables reported within Table S1 were included in the linear regression model.

Factor analysis of the BBI

As shown in Table 5, utilizing patient data, five independent factors were identified using varimax rotation. An oblique methodology was also employed using a direct oblimin rotation (delta = 0) which identified identical principle components within the factor structures, though the rank order of the factors differed (see Table S2). Although the BBI focuses on dysexecutive behavior, Factor 1 identified in the model accounts for the greatest amount of variance, which describes a broad range of disinhibited items of the scale (i.e., acts without thinking; acts inappropriately; excessively stores food in mouth; and hyperorality), Factor 2 reflects a clustering of items related to an irregularity of reward and impulse control (i.e., eats much more, is less picky about food, smokes more, is more distractible, etc.). Factor 3 reports dysexecutive behaviors (i.e., aggressive behavior, irritability, less concern about hygiene, and less concern for others). Factor 4 details a group of behaviors focusing around cognitive rigidity (i.e., overly concerned with neatness, aligning things a certain way, checking clocks/switches). Factor 5 is reflective of behavioral changes likely to be seen within ALSFTD, and are characterized by their neuropsychiatric nature (i.e., visual and auditory hallucinations, new bizarre beliefs, hoards/hides/collects things, and handles things for no apparent reason). Many of the behaviors apparent in Factor 5 were represented within the C9orf72‐positive group. Table S3 shows the breakdown between ALS patients and healthy controls based on the itemized loading onto factors within the BBI, and the comparative result. See Figure S2 for a behavioral schema of these factors.
Table 5

Item loading and relevant cross‐loading into five identified factors (varimax rotation)

Beaumont behaviour inventory questionsIdentified BBI components
12345
1Repeats words/sentences said by others 0.745
Not aware of mistakes 0.647
Excessively stores food in mouth 0.632
More withdrawn 0.607 0.442
Lack of embarrassment 0.594
Acts without thinking 0.580
Difficulties with conversation 0.564
Difficulty with everyday language 0.550 0.471
Less able to react to difficulties 0.549
Hyperorality 0.541
Repeats phrases again and again 0.520 0.482
Acts inappropriately in public 0.481
Obsessive countinga 0.306
Seeks social contact 0.672
Shows less emotion 0.623
More distractible/unable to concentrate 0.539
2New food preferences 0.502
Dislikes change in routine 0.448
Smokes more 0.415
Eats much morea 0.270
Less picky about food preferencesa 0.245
New unusual habits 0.621
More aggressive 0.617
Less concerned about others0.496 0.543
Increased irritability 0.497
Perseverative speech 0.478
3More selfish 0.474
Less concerned about hygiene0.460 0.464
Emotional lability 0.444
Repetitious behaviora 0.383
Overly sensitive to sensations (noise)a 0.371
Less aware of physical sensationa 0.326
Developed unusual ritualsa 0.297
Overly concerned with neatness 0.751
4Constantly aligns things in a certain way 0.720
Constantly checking clocks/switches0.477 0.483
Change in sexual interest 0.441
Sees/Hears Things/People 0.839
5Handles things for no apparent reason 0.736
New bizarre beliefs 0.674
Hoards, hides, or collects things 0.586
Variance explained24.46.25.74.64.1

Extraction Method: Principal Component Analysis. Rotation Method: Varimax with Kaiser Normalization. Bold figures display which factor the items loaded best with. BBI, Beaumont Behavioural Inventory.

Items which are considered weak, that is, <0.4, which do not load to an individual factor.

Item loading and relevant cross‐loading into five identified factors (varimax rotation) Extraction Method: Principal Component Analysis. Rotation Method: Varimax with Kaiser Normalization. Bold figures display which factor the items loaded best with. BBI, Beaumont Behavioural Inventory. Items which are considered weak, that is, <0.4, which do not load to an individual factor.

The C9orf72 expansion and behavior change in ALS

C9orf72 hexanucleotide repeat screening was undertaken in 308/317 ALS patients (97.16%). Of the patients who had not undergone genetic testing, seven had no significant behavior change, and two fell within the mild‐moderate range. Forty of the ALS patients tested (12.98%) were positive for the C9orf72 hexanucleotide repeat expansion. These patients were significantly younger at time of testing compared to patients without the genetic expansion (59.8 ± 9.0 vs. 63.7 ± 11.26, P = 0.037). The presence of the positive C9orf72 gene expansion was associated with greater caregiver endorsement on the BBI, although 40% of these patients had no significant behavior change (n = 16); 40% were reported to have mild‐moderate behavioral change; the remaining 20% (n = 8) were within the Clinically Severe Behavioral Change group. Four patients with the C9orf72 gene expansion had evidence of cognitive impairment, two within the mild‐moderate behavior change group, and two within the Clinically Severe Behavioral Change group. C9orf72‐positive patients were less aware of mistakes (45% vs. 22.7%; P = 0.007); were more aggressive (25% vs. 15.5%; P = 0.026); reported seeing/hearing things/people (7.7% vs. 1.7%; P = 0.031); demonstrated new bizarre beliefs (14.3% vs. 3.5%; P = 0.024); and showed evidence of hoarding, hiding, or collecting objects (15% vs. 5.8%; P = 0.045).

ALS patient survival and behavior change

Of the total cohort of 317 patients tested, 175 are deceased. Of these, 85 had no behavioral change; 65 had mild‐moderate behavioral change, and 25 patients were within the clinically severe range. As seen in Figure 3, there was no significant difference between the groups at the beginning of the survival curve (Breslow P = 0.105), middle (Tarone‐Ware P = 0.139), or end (Log Rank P = 0.198), implying that behavior change, as assessed early in the disease, was not a predictor of survival.
Figure 3

Survival data of ALS patients (n = 175) stratified by the severity of behavioral change.

Survival data of ALS patients (n = 175) stratified by the severity of behavioral change.

Discussion

The aim of this study was to examine behavioral change in a large population‐based cohort of ALS patients using a validated disease‐specific behavioral scale. Our data confirm those of previous studies that emotional lability is a frequent finding in ALS (44%). Other common behavioral changes included a reduced concern for hygiene (36.8%), increased irritability (36.2%), new unusual habits (33.4%), and increased apathy (31.1%). As noted previously, 37% of patients with behavioral change were cognitively normal. Emotional lability, or “pseudobulbar affect” is recognized as a manifestation of extensive upper motor neuron pathology, and is generally considered separately from other types of behavioral change. In our cohort, increased rates of emotional lability were associated with bulbar‐onset disease, which is congruent with other studies. Emotional lability is considered to be a disconnection between mechanisms which mediate emotions and associated motor responses, and primarily presents secondary to lesions, atrophy, or injury to the cortico‐limbic‐subcortico‐thalamic‐ponto‐cerebellar network.41 The majority of patients exhibiting mild behavior change had evidence of emotional lability (57.4%). Apathy was also commonly reported (48.4%). This cohort further exhibited new‐onset unusual habits (44.7%) and less concern for hygiene (52.1%). Patients with severe behavioral impairment exhibited apathy (87.5%); were not as aware of mistakes as before (82.5%), more impulsive (82.9%), and less responsive to others' needs (71.4%). Clinically relevant behavioral changes were also noted, that is, increased sensitivity to sensory stimuli (>28%), likely resulting from pathophysiological changes in the afferent system.42 Our findings concur with previous findings which suggest that behavioral changes in ALS are qualitatively similar regardless of whether a patient presents with mild or more severe behavior change.8, 15 These qualitative similarities likely represent shared disrupted neurologic pathways, with greater atrophy resulting in increased behavioral severity as seen with other neurodegenerative conditions. Notwithstanding, some behaviors, that is, hallucinations, were almost exclusively present in the Clinically Severe Behavioral Change group (See Tables 3 and 4). Our findings extend those of previous studies both by the large size of the study population, and by our data‐driven observations indicating that specific behavioral subphenotypes can be discerned in ALS to a greater extent than previously reported.9, 43 By mapping, from a neuropsychological perspective, these altered behaviors onto known anatomic pathways, the behavioral categories broadly reflect differential impairments within the corticostriatal circuits known to be compromised in ALS. For example, the neuropsychological categorization of behaviors within Factor 1 are reflective of disruptions in pathways involving medial prefrontal and orbitofrontal cortices, as well as the anterior insula.44, 45 Behaviors characteristics within Factor 2 implicate orbitofrontal and anterior cingulate pathways46, 47; and those within Factor 3 are suggestive of disruptions in right prefrontal regions.48, 49, 50, 51 The clusters of behavioral change within Factor 4 are associated with alterations in the dorsolateral prefrontal cortex and temporolimbic networks.52, 53 Behaviors described by Factor 5 are not predictive of specific neuroanatomical pathways but are closely associated with the C9orf72 expansion which is known to implicate extensive cortical and subcortical frontotemporal regions.24 See Figure S1 for a graphical illustration of the behavioral schema. Further analysis of behavioral impairment in ALS demonstrated that changes occurred in a mutually exclusive manner, which adds validity to the findings (see Table 5). This is evident through the statistical convergence, that is, Factor 1: “Lack of Embarrassment”, and “Acts Inappropriately in Public” occurred together. Moreover, the statistical divergence of the scale items illustrates the exclusivity of these behavioral changes between different factor, that is, Factor 1: “More Withdrawn”, and Factor 2: “Seeks Social Contact”. Employing an oblique rotation method yielded identical factor structures (Table S2), however, the rank order differed. Using the oblimin rotation, the factor which represented C9orf72 features was more closely correlated with the primary factor, that is, disinhibition. Clinically, this finding reflects the widely reported association between these observed behaviors, and the C9orf72 expansion in ALS patients.2, 3, 4, 9, 10, 12, 13, 15, 16 The cumulative variance accounted for by our principal component analysis are consistent with the methodology employed, whereby one principal factor is identified (Factor 1: See Table 5), with subcomponents identified which carry less variance. These factors met the stringent statistical cut‐off of behaviors which cluster together in ALS. Considering these data, the BBI should be considered as a reliable and valid tool for identifying behavioral change in ALS when the total score is adopted, as previously reported (Cronbach's alpha = 0.906). However, considering these data, specific subdomains of behavioral clusters have been outlined which may represent specific behavioral phenotypes in ALS, and specific subscales of the BBI. One of the mostly widely accepted nondysexecutive behavioral subphenotype in ALS2, 54 relates to Factor 5 which, from a neuropsychological perspective, is predictive of more extensive network disruption. In our study cohort, this constellation of behavioral change was associated primarily with the presence of the C9orf72 expansion.54 In our cohort, 20% (n = 8) of the C9orf72‐positive patients met the cut‐off score for clinically severe change, which according to the BBI, is suggestive of bvFTD.26 Extensive cognitive assessments were conducted with a subcohort of ALS patients (n = 65). Although 37% of patients with behavioral change were cognitively normal, there were significant correlations between the measures of executive function (Stroop Colour‐Word Interference Task, VFI and the Brixton Spatial Anticipation task) and severe behavioral change. Notably, these tasks are dependent on the integrity of multiple frontostriatal circuits, requiring both inhibition of unwanted responses and close error monitoring.55 More severe behavioral impairment also correlated with lower scores on the RMET, which was a reliable predictor of behavioral change in ALS. Overall, these data confirm the relationship between executive function and severe behavioral change and infer that behavior changes in ALS are associated with frontal pathology. Indeed, the strongest predictor of behavioral change in our neuropsychological model was a measure of social cognition, which anatomically correlates with core circuitry involving the dorsolateral prefrontal cortical regions and the anterior cingulate.56 Although primarily cross‐sectional in nature, the large population‐based sample permitted an assessment of the relationship between behavioral change and disease stage as defined by the King's Staging System. Our findings suggest that while physical disability may contribute to milder degrees of behavioral impairment, it is unlikely to be a major determinant of overall behavioral impairment. We found no significant differences on survival between the groups with and without behavioral impairment, in contrast to our previous findings that executive impairment is a significant negative prognostic indicator.57 This study has limitations. The data are drawn from a cross‐sectional analysis, albeit with survival data, and longitudinal analyses are required to confirm our findings. Although this study incorporated a relatively large cohort of C9orf72‐positive patients, larger samples with differing behavioral profiles are required. Notwithstanding, this study, which to the best of our knowledge is the largest analysis of behavioral change in ALS to date and facilitates for the first time a factor analysis of behavior, has identified a characteristic behavioral phenotype associated with the C9orf72 repeat expansion, and several further behavioral subphenotypes. These factor loadings represent the psychometric and statistical clustering of the items on the scale, and further external validation studies are needed, as well as neuroimaging data or postmortem analyses to confirm the behavioral mapping to neuropathological regions, known to be implicated in ALS. Our neuropsychology‐based analyses support the hypothesis that behavioral subphenotypes in ALS reflects differential disruption of extramotor networks involving frontostriatal, orbitofrontal, and anterior cingulate pathways and indicate that the neuropsychological profile of ALS patients that manifest as behavioral change is heterogeneous, reflecting differential disruption of neuroanatomic circuits. Further longitudinal studies are currently underway to assess the interaction between behavioral change and clinical staging, and between neuropsychological changes and those observed by neuroimaging.

Author Contribution

TB contributed to the process of data collection, analyzed the data and wrote the manuscript; PB, AV, RLM, KL, MOS, and MPG contributed to the process of data collection, edited, and revised the intellectual content of the manuscript; NP supervised the neuropsychological and statistical aspects of the study and revised the manuscript from a neurocognitive and behavioral perspective; and OH supervised all clinical aspects of the study in all stages of development and revised the manuscript from a clinical perspective.

Conflict of Interest

Dr Tom Burke, Ms Marta Pinto‐Grau, Dr Peter Bede, Ms. Katie Lonergan, Dr Alice Vajda, Dr Russell McLaughlin, Mr Mark Heverin, and Dr Niall Pender have nothing to disclose. Prof. Orla Hardiman has received fees for consultation work from Biogen Idec, Cytokinetics, and Novartis. She serves as Editor‐in‐Chief of Amyotrophic Lateral Sclerosis. The authors report no conflict of interests. Figure S1. Scree plot derived from the factor analysis of BBI data. Click here for additional data file. Figure S2. A schema of the identified behavioral factors and their neuroanatomical correlates based on the literature. mPFC: medial prefrontal cortex; OFC: orbitofrontal cortex; aI: anterior Insula; ACC: anterior cingulate; dlPFC: dorsolateral prefrontal regions TL temporolimbic area. Factor 1: mPFC‐OFC‐aI (black); Factor 2: OFC‐ACC (blue); Factor 3: OFC‐ mPFC‐dlPFC (red); Factor 4: dlPFC‐OFC‐TL (orange). See Bede et al., 2013 for characteristics of cortical and subcortical changes in ALS with the C9orf72 expansion. Click here for additional data file. Table S1. Additional data on the subcohort completing the cognitive assessment. Table S2. Item loading and cross‐loading on five identified factors (oblique method, oblimin rotation). Table S3. Frequency of all reported behaviors in the ALS cohort versus healthy controls. Click here for additional data file.
  54 in total

1.  Behaviour in amyotrophic lateral sclerosis.

Authors:  Zoe C Gibbons; Anna Richardson; David Neary; Julie S Snowden
Journal:  Amyotroph Lateral Scler       Date:  2008-04

Review 2.  The reward circuit: linking primate anatomy and human imaging.

Authors:  Suzanne N Haber; Brian Knutson
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

Review 3.  The cognitive profile of ALS: a systematic review and meta-analysis update.

Authors:  Emma Beeldman; Joost Raaphorst; Michelle Klein Twennaar; Marianne de Visser; Ben A Schmand; Rob J de Haan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-08-17       Impact factor: 10.154

4.  Cognition and behaviour are independent and heterogeneous dimensions in Alzheimer's disease.

Authors:  Gianfranco Spalletta; Francesca Baldinetti; Ivana Buccione; Lucia Fadda; Roberta Perri; Silvia Scalmana; Laura Serra; Carlo Caltagirone
Journal:  J Neurol       Date:  2004-06       Impact factor: 4.849

Review 5.  Neuroanatomy of pathological laughing and crying: a report of the American Neuropsychiatric Association Committee on Research.

Authors:  Josef Parvizi; Kerry L Coburn; Samuel D Shillcutt; C Edward Coffey; Edward C Lauterbach; Mario F Mendez
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2009       Impact factor: 2.198

6.  Cognitive changes predict functional decline in ALS: a population-based longitudinal study.

Authors:  Marwa Elamin; Peter Bede; Susan Byrne; Norah Jordan; Laura Gallagher; Brona Wynne; Caoimhe O'Brien; Julie Phukan; Catherine Lynch; Niall Pender; Orla Hardiman
Journal:  Neurology       Date:  2013-04-03       Impact factor: 9.910

7.  Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis.

Authors:  Michael J Strong; Gloria M Grace; Morris Freedman; Cathy Lomen-Hoerth; Susan Woolley; Laura H Goldstein; Jennifer Murphy; Christen Shoesmith; Jeffery Rosenfeld; P Nigel Leigh; Lucie Bruijn; Paul Ince; Denise Figlewicz
Journal:  Amyotroph Lateral Scler       Date:  2009-06

8.  Gender differences in the behavioral manifestations of Alzheimer's disease.

Authors:  B R Ott; C A Tate; N M Gordon; W C Heindel
Journal:  J Am Geriatr Soc       Date:  1996-05       Impact factor: 5.562

9.  Metacognitive and online error awareness deficits after prefrontal cortex lesions.

Authors:  Doreen Hoerold; Niall P Pender; Ian H Robertson
Journal:  Neuropsychologia       Date:  2012-11-27       Impact factor: 3.139

10.  Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale.

Authors:  Rubika Balendra; Ashley Jones; Naheed Jivraj; Catherine Knights; Catherine M Ellis; Rachel Burman; Martin R Turner; P Nigel Leigh; Christopher E Shaw; Ammar Al-Chalabi
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-04-10       Impact factor: 4.092

View more
  18 in total

1.  The Study of Language in the Amyotrophic Lateral Sclerosis - Frontotemporal Spectrum Disorder: a Systematic Review of Findings and New Perspectives.

Authors:  Marta Pinto-Grau; Orla Hardiman; Niall Pender
Journal:  Neuropsychol Rev       Date:  2018-04-28       Impact factor: 7.444

Review 2.  The imaging signature of C9orf72 hexanucleotide repeat expansions: implications for clinical trials and therapy development.

Authors:  Stacey Li Hi Shing; Mary Clare McKenna; We Fong Siah; Rangariroyashe H Chipika; Orla Hardiman; Peter Bede
Journal:  Brain Imaging Behav       Date:  2021-01-05       Impact factor: 3.978

3.  Extra-motor cerebral changes and manifestations in primary lateral sclerosis.

Authors:  Eoin Finegan; Stacey Li Hi Shing; Rangariroyashe H Chipika; Kai Ming Chang; Mary Clare McKenna; Mark A Doherty; Jennifer C Hengeveld; Alice Vajda; Niall Pender; Colette Donaghy; Siobhan Hutchinson; Russell L McLaughlin; Orla Hardiman; Peter Bede
Journal:  Brain Imaging Behav       Date:  2021-01-07       Impact factor: 3.978

4.  Extra-motor manifestations in post-polio syndrome (PPS): fatigue, cognitive symptoms and radiological features.

Authors:  Stacey Li Hi Shing; Jasmin Lope; Rangariroyashe H Chipika; Orla Hardiman; Peter Bede
Journal:  Neurol Sci       Date:  2021-02-26       Impact factor: 3.307

5.  Assessing behavioural changes in ALS: cross-validation of ALS-specific measures.

Authors:  Marta Pinto-Grau; Emmet Costello; Sarah O'Connor; Marwa Elamin; Tom Burke; Mark Heverin; Niall Pender; Orla Hardiman
Journal:  J Neurol       Date:  2017-06-09       Impact factor: 4.849

Review 6.  Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis.

Authors:  Colin J Mahoney; Rebekah M Ahmed; William Huynh; Sicong Tu; Jonathan D Rohrer; Richard S Bedlack; Orla Hardiman; Matthew C Kiernan
Journal:  CNS Drugs       Date:  2021-05-15       Impact factor: 5.749

7.  Regional prefrontal cortical atrophy predicts specific cognitive-behavioral symptoms in ALS-FTD.

Authors:  Elena Ratti; Kimiko Domoto-Reilly; Christina Caso; Alyssa Murphy; Michael Brickhouse; Daisy Hochberg; Nikos Makris; Merit E Cudkowicz; Bradford C Dickerson
Journal:  Brain Imaging Behav       Date:  2021-02-15       Impact factor: 3.224

Review 8.  Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis.

Authors:  Stephen A Goutman; Orla Hardiman; Ammar Al-Chalabi; Adriano Chió; Masha G Savelieff; Matthew C Kiernan; Eva L Feldman
Journal:  Lancet Neurol       Date:  2022-03-22       Impact factor: 59.935

9.  Mismatch Negativity as an Indicator of Cognitive Sub-Domain Dysfunction in Amyotrophic Lateral Sclerosis.

Authors:  Parameswaran Mahadeva Iyer; Kieran Mohr; Michael Broderick; Brighid Gavin; Tom Burke; Peter Bede; Marta Pinto-Grau; Niall P Pender; Russell McLaughlin; Alice Vajda; Mark Heverin; Edmund C Lalor; Orla Hardiman; Bahman Nasseroleslami
Journal:  Front Neurol       Date:  2017-08-15       Impact factor: 4.003

10.  11 C-PK11195 PET-based molecular study of microglia activation in SOD1 amyotrophic lateral sclerosis.

Authors:  Giacomo Tondo; Leonardo Iaccarino; Chiara Cerami; Giovanna Emilia Vanoli; Luca Presotto; Valeria Masiello; Angela Coliva; Fabrizio Salvi; Ilaria Bartolomei; Lorena Mosca; Christian Lunetta; Daniela Perani
Journal:  Ann Clin Transl Neurol       Date:  2020-08-06       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.